NCT01664260

Efficacy Mechanism of N-acetylcysteine in Patients With Posttraumatic Stress Disorder

Elucidation of Efficacy Mechanism of N-acetylcysteine in Patients With Posttraumatic Stress Disorder: An 8-week Multimodal Neuroimaging and Neurocognitive Study

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Ewha Womans University · Academic / Other
• Sex: All
• Age: 20 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

It has been suggested that N-acetylcysteine exerts neuroprotective effects by regulating neurotransmitters and cell signaling pathways. We hypothesize that oral N-acetylcysteine augmentation will help reduce symptoms in patients with posttraumatic stress disorder as well as improve cognitive functions. We also expect that the N-acetylcysteine augmentation will induce change in structural, functional, and neurochemical aspects of the brain. In this study, we plan to conduct a randomized, double-blind, placebo-controlled augmentation study with N-acetylcysteine in addition to escitalopram. We will assess the efficacy and safety of the N-acetylcysteine augmentation.

Conditions

• Posttraumatic Stress Disorder

Interventions

Type	Name	Description
DRUG	N-acetylcysteine	0 - 8 week: 10 mg escitalopram a day + 1200 mg N-acetylcysteine twice a day
DRUG	Placebo	0 - 8 week: 10 mg escitalopram a day + 1200 mg Placebo twice a day

Timeline

• Start date: 2012-11-01
• Primary completion: 2016-12-01
• Completion: 2016-12-31
• First posted: 2012-08-14
• Last updated: 2018-02-09

Locations

1 site across 1 country: South Korea